Akari Therapeutics (AKTX) Receives Daily News Sentiment Score of 0.03
Media coverage about Akari Therapeutics (NASDAQ:AKTX) has trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akari Therapeutics earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.7670625353809 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Akari Therapeutics stock traded up $0.02 during trading on Friday, hitting $1.84. The stock had a trading volume of 21,297 shares, compared to its average volume of 107,756. The firm has a market capitalization of $22.49 million, a PE ratio of -6.57 and a beta of -7.53. Akari Therapeutics has a 12 month low of $1.70 and a 12 month high of $11.95.
Separately, ValuEngine upgraded shares of Akari Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $5.33.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.
Further Reading: Analyst Ratings
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.